BEDMINSTER, N.J., and DUBLIN, Ireland, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced details for its planned conference call to discuss the results of the U.S. Food and Drug Administration (FDA) advisory committee meeting in connection with the FDA’s review of the supplemental New Drug Application (sNDA) seeking approval for the use of Vascepa® (icosapent ethyl) capsules in the proposed ANCHOR indication, as an adjunct to diet in the treatment of adult patients with high triglycerides (TG =200 mg/dL and <500 mg/dL) with mixed dyslipidemia. Members of Amarin senior management will host this event on Wednesday, October 16, 2013, at 7:00 p.m. ET, following the conclusion of the ANCHOR advisory committee meeting scheduled for earlier that day.
Help employers find you! Check out all the jobs and post your resume.
